



MOLECULAR TEMPLATES

Company Overview

Molecular Templates is focused on the discovery, development, and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases.

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

Mar 29 2024, 8:21 AM EDT

Molecular Templates Announces \$9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement

Mar 28 2024, 8:11 AM EDT

Molecular Templates, Inc. Provides Interim Update

Mar 4 2024, 8:11 AM EST

Stock Overview

Symbol	MTEM
Exchange	Nasdaq
Market Cap	10.64m
Last Price	\$1.98
52-Week Range	\$1.68 - \$9.45

04/08/2024 03:57 PM EDT

Investor Relations

Dr. Grace Kim
grace.kim@mtem.com

Management Team

Eric Poma, Ph.D.

Chief Executive Officer & Chief Scientific Officer

Jason Kim

President & Chief Financial Officer

Dr. Maurizio Voi

Chief Medical Officer

Kristen Quigley

Chief Operating Officer

Grace Kim

Chief Strategy Officer & Head of Investor Relations

Joseph Phillips, Ph.D.

Senior Vice President and Head of CMC Development

Molecular Templates, Inc.

9301 Amberglen Blvd
Suite 100
Austin, TX 78729

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.